Fund moves
6.2%Stake
A Schedule 13D means the holder owns more than 5% and keeps the option to push for changes: board seats, a sale, buybacks. It must be filed within 5 business days.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
SOPH · NASDAQ · Services-Computer Processing & Data Preparation · Foreign private issuer
Sophia Genetics (SOPH) · oqro.io/stocks/SOPH · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$8.21+0.35 (+4.45%)
Close of Nov 13, 2026, vs Nov 12 · end-of-day, not a live quote
Yes. Insiders of Sophia Genetics (SOPH) filed 2 open-market purchases in the last 90 days; the latest was filed on Nov 9, 2026.
Since 2026, Sophia Genetics insiders reported 2 open-market purchases and 6 sales on Forms 4 and 5, with purchases in 1 different year, most recently 2026.
In the last 90 days, 5 insiders of Sophia Genetics (SOPH) reported 6 open-market sales worth $252K in total on SEC Form 4. The largest seller by value was Jurgi Camblong, with $128K. Many insider sales follow a plan set in advance or cover taxes on stock awards; the filing says what was sold, not the reason.
No trade in Sophia Genetics (SOPH) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
+87.4% (+$3.83) from Nov 13, 2025 to Nov 13, 2026 · adjusted daily closes
Adjusted close went from $4.38 on Nov 13, 2025 to $8.21 on Nov 13, 2026 (+87.4%). Disclosed in this range: 2 insider trades, 6 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Services-Computer Processing & Data Preparation company based in Rolle, Switzerland. Foreign private issuer: reports on Form 20-F or 40-F.
Services-Computer Processing & Data Preparation company based in Rolle, Switzerland. Foreign private issuer: reports on Form 20-F or 40-F. Its directors and officers file insider-trading forms (Form 4) only since 18 March 2026.
Last 12 months
+87.4%
Market value
$562M
S&P 500 +12.3% over the same dates. Prices adjusted for splits and dividends.
Short interest: 1.15M shares sold short (1.7% of shares outstanding), +14.8% vs the previous count, 2.6 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Fund moves
A Schedule 13D means the holder owns more than 5% and keeps the option to push for changes: board seats, a sale, buybacks. It must be filed within 5 business days.
Jurgi Camblong (Executive Chairman) sold ~$66K of Sophia Genetics
Planned saleKathy L Hibbs (Director) sold ~$48K of Sophia Genetics
Planned saleWell Daan Van (Chief Legal Officer) sold ~$10K of Sophia Genetics
Planned saleInsider buying
First insider buy on recordTraded Nov 6 · filed 3 days later
Since the trade +15.0% · S&P 500 +2.6% · to Nov 13
The CFO of Sophia Genetics paid $141K out of pocket for Sophia Genetics shares. 1 other person at Sophia Genetics bought some too, in the same month. Shares held went up 7% with this purchase.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Anyone owning more than 5% must file within days. Structured filings have existed since December 2024, so older stakes that were never amended may be missing.
Written by software from the filings listed below · Nov 13, 2026
4 more points, with the facts they come from, are in OQRO Pro.
Sign up free2 certified in FY2026 Q3, vs 1 a year earlier. 2 positions in total, median offered wage $125K a year.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
Insiders of Sophia Genetics reported 2 open-market purchases and 6 sales since 2026; purchases in 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $278K2×2 trades | $252K6×6 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Against the S&P 500 over the year
Since Nov 11, 2025, SOPH is up 77.7% and the index fund is up 10.4%: 67 points ahead of the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much SOPH moves
End-of-day prices. These figures describe the past year and say nothing about what comes next.